A reduced 30 mg edoxaban daily dose was given in 22% of patients without diabetes, 26% of diabetic patients not on insulin and 38% of those on insulin; the prevalence of a concomitant antiplatelet treatment at baseline was 14.7, 17.2 and 17.2%, respectively. The gene discussed is INS; the disease is diabetes mellitus.